Adam M. Brufsky, MD, PhD
Major changes for patients with HER2- positive breast cancer are not on the horizon, but there are a number of new study findings that have amplified knowledge about how best to care for this population.
Dual-Targeted Neoadjuvant Therapy: Pertuzumab Plus Trastuzumab With Chemotherapy
Adam M. Brufsky, MD, PhD, session moderator, began the discussion by observing that interesting abstracts at SABCS covered both early and late disease. Neoadjuvant therapy in HER2-positive breast cancer has been a tremendous success, he said, noting research on determining the optimal chemotherapy backbone for using neoadjuvant trastuzumab (Herceptin) plus pertuzumab (Perjeta).
... to read the full story